All In Biotech

Drug Trial Radar · NCT00768274

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Sep 2008

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
First posted
Oct 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.

Conditions

  • Dyslipidemia
  • Atherosclerosis
  • Acute Coronary Syndrome
  • Cardiovascular Disease

Interventions

  • RVX000222Drug

    RVX000222 twice daily (b.i.d.) for 28 days

  • PlaceboDrug

    Placebo twice daily (b.i.d.) for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety, pharmacokinetics and changes in lipid parameters from baseline and placebo.Time frame: 1-month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit, Inc.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.